IRADIMED CORP — Director's Dealing 2020

Mar 5, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: IRADIMED CORP (IRMD)
CIK: 0001325618
Period of Report: 2020-03-02

Reporting Person: JOHNSON BRENT (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-03-02	Common Stock	M	13710	$0.93	Acquired	16650	Direct
2020-03-02	Common Stock	S	13710	$23.87	Disposed	2940	Direct
2020-03-03	Common Stock	M	13010	$0.93	Acquired	15950	Direct
2020-03-03	Common Stock	S	13010	$24	Disposed	2940	Direct
2020-03-04	Common Stock	M	6954	$0.93	Acquired	9894	Direct
2020-03-04	Common Stock	S	6954	$23.8	Disposed	2940	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-03-02	Stock Option (Right to Buy)	$0.93	M	13710	Disposed	2022-11-01	Common Stock (13710)	Direct
2020-03-03	Stock Option (Right to Buy)	$0.93	M	13010	Disposed	2022-11-01	Common Stock (13010)	Direct
2020-03-04	Stock Option (Right to Buy)	$0.93	M	6954	Disposed	2022-11-01	Common Stock (6954)	Direct

Footnotes

F1: The exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2019.

F2: This transaction was executed in multiple trades at prices ranging from $23.65 to $24.16. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F3: This transaction was executed in multiple trades at prices ranging from $23.85 to $24.40. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F4: This transaction was executed in multiple trades at prices ranging from $23.62 to $24.07. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F5: This option, representing a right to purchase a total of 278,408 shares, was granted on November 1, 2012 and vests over 4 years in equal annual installments commencing on the first anniversary of the grant date.